November 21, 2026

US panel to weigh unapproved drug-coated stent use

Advisers to the US Food and Drug Administration on Friday will consider the risks of drug-coated stents in patients with medical complications who are not approved for the artery-opening heart devices.

bdnews24.com News Service

bdnews24.com

Published : 07 Dec 2006, 06:00 PM

Updated : 17 Aug 2022, 06:59 PM

WASHINGTON, Dec 8 (bdnews24.com/Reuters) - Advisers to the US Food and Drug Administration on Friday will consider the risks of drug-coated stents in patients with medical complications who are not approved for the artery-opening heart devices. The risk of blood clots linked to the devices -- tiny mesh tubes that keep arteries open after doctors clear them of blockages -- are the focus of a two-day review by an FDA advisory panel of outside experts. More than half of the devices are used in patients with complex cases such as those with severe heart attacks or totally blocked arteries -- conditions not approved by the FDA. Doctors still can implant the stents if they think a patient may benefit. Drug-coated stents, sold in the United States by Johnson & Johnson and Boston Scientific Corp, had been considered a major step in helping prevent arteries from reclogging, a problem reported in about a quarter of bare-metal stent procedures. Still, many doctors have begun reconsidering their use of drug-coated stents in light of blood clot concerns. On Thursday, Boston Scientific and Johnson & Johnson told the FDA panel their products are safe for a broad range of patients, despite recent research that showed they may cause blood clots months after implantation. "There is no reason to believe the current clinical use exposes complex patients to excess risk compared to other alterative (artery-clearing) therapies," said Boston Scientific Chief Medical and Scientific Officer Donald Baim. Representatives for Johnson & Johnson unit Cordis said stents are used for unapproved patients because there are no alternatives, adding that data did not signal a safety concern. An FDA analysis concluded there was a 'small but significant' risk of blood clots a year or more after a drug-coated stent is placed. Earlier on Thursday, the panel of cardiologists and other experts voiced mixed views about whether the limited data collected so far truly showed higher clotting and what level of risks patients face. "The magnitude of the risk is uncertain," said panel chairman Dr William Maisel of Beth Israel Deaconess Medical Centre. Members agreed, however, that drug-coated stents did not lead to more heart attacks or deaths - potential complications of blood clots. Overall, the panel unanimously said the benefits of drug-coated stents outweigh their risks as long as they are used as intended. It is still unclear what impact the panel's recommendations will have on the nearly 6 million patients worldwide who analysts estimate have received drug-coated stents. The effect on the $6 billion-a-year stent market is also uncertain. Some analysts say Wall Street has already concluded the panelists will not call for drastic action. Two other devicemakers -- Abbott Laboratories Inc and Medtronic Inc -- are seeking to sell their drug-coated stents in the United States as early as next year. Shares of Johnson & Johnson and Boston Scientific Corp got a brief boost on Thursday from the panel's support but later closed near unchanged. bdnews24.com/srs/1329 hrs
Related Stories